Alterity Therapeutics Ltd: Form 20-F for the period ended Jun 30, 2020
Filed with the SEC on Sep 15, 2020 and accepted by EDGAR at Sep 15, 2020, 06:19 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Interest expense | 12 months2019-07-01 to 2020-06-30 | AUD 3.9k | us-gaap:InterestExpense |
| Operating cash flow | 12 months2019-07-01 to 2020-06-30 | −AUD 9.4m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months2019-07-01 to 2020-06-30 | AUD 16.7k | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | At period end2020-06-30 | AUD 9.2m | ifrs-full:CashAndCashEquivalents |
| Current assets | At period end2020-06-30 | AUD 9.8m | ifrs-full:CurrentAssets |
| Total assets | At period end2020-06-30 | AUD 9.9m | ifrs-full:Assets |
| Current liabilities | At period end2020-06-30 | AUD 2.7m | ifrs-full:CurrentLiabilities |
| Total liabilities | At period end2020-06-30 | AUD 2.8m | ifrs-full:Liabilities |
| Shareholders' equity | At period end2020-06-30 | AUD 7.2m | ifrs-full:Equity |
| Shares outstanding | At period end2020-06-30 | 1,037,358,032 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001213900-20-026557. Last ingested by Listed: Oct 30, 2026, 06:15 ET. Listed shows no prices and gives no investment advice.